Trump has begun another trade war. Here's a timeline of how we got here
Canada's leader laments lost friendship with US in town that sheltered stranded Americans after 9/11
Chinese EV giant BYD's fourth-quarter profit leaps 73%
You're an American in another land? Prepare to talk about the why and how of Trump 2.0
Chalk talk: Star power, top teams and No. 5 seeds headline the women's March Madness Sweet 16
Purdue returns to Sweet 16 with 76-62 win over McNeese in March Madness
(Reuters) - GE HealthCare forecast 2024 profit largely above Wall Street expectations and beat fourth-quarter profit estimates on strong demand for its imaging devices, sending the company's shares up 2% before the bell on Tuesday.
Demand for medical devices has seen a post-pandemic surge as customers, particularly older adults, in the United States are returning to hospitals for procedures such as hip and knee replacements.
Companies such as Johnson & Johnson and Boston Scientific topped sales estimates in the medical devices segment during their quarterly results.
GE HealthCare has four medical device businesses - imaging, ultrasound, patient care solutions and pharmaceutical diagnostics - with imaging being the largest.
The company's imaging segment reported revenue of $2.83 billion, narrowly beating estimates of $2.82 billion, according to LSEG data.
On an adjusted basis, GE HealthCare expects an annual profit of $4.20 to $4.35 per share, the midpoint of which was above estimates of $4.22.
Excluding items, the company earned $1.18 per share in the fourth quarter, compared to estimates of $1.07.
GE HealthCare reported total revenue of $5.21 billion, beating analysts' expectations of $5.09 billion.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shounak Dasgupta)
